| Identification | Back Directory | [Name]
Multi-kinase inhibitor 3 | [CAS]
2648279-76-7 | [Synonyms]
Multi-kinase inhibitor 3
Benzeneacetamide, N-[3-(1,1-dimethylethyl)-5-isoxazolyl]-4-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- | [Molecular Formula]
C26H26N6O2 | [MOL File]
2648279-76-7.mol | [Molecular Weight]
454.52 |
| Hazard Information | Back Directory | [Uses]
Multi-kinase inhibitor 3 (compound 12) is a potent and orally active multikinase inhibitor with IC50 values of 1.59, 1.23, 1.19, 0.59, 0.22, 1.15 nM for FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, PDGFRβ, respectively. Multi-kinase inhibitor 3 shows antiproliferative activity. Multi-kinase inhibitor 3 shows anticancer activity[1]. | [IC 50]
VEGFR1: 1.59 nM (IC50); VEGFR2: 1.23 nM (IC50); VEGFR3: 1.19 nM (IC50); PDGFRα: 0.22 nM (IC50); PDGFR-β: 1.15 nM (IC50) | [References]
[1] Das D, et al. Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models. Bioorg Med Chem Lett. 2024 Sep 19;113:129971. DOI:10.1016/j.bmcl.2024.129971 |
|
|